187 results about "Immune adjuvant" patented technology

The invention is directed to novel compounds of formulae (I), (II) and (III): wherein X is O or NH; R3 is OH or a monosaccharide and R4 is hydrogen, or R3 is hydrogen and R4 is OH or a monosaccharide; R5 is hydrogen or a monosaccharide; and pharmaceutically acceptable salts or esters thereof. The invention is also directed to the use of the compounds both directly and as immune adjuvants for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the intermediates which can be used to make these novel compounds.

Fusion proteins and DNA conjugates are disclosed which contain a TLR / CD40 / agonist and optional antigen combination. The use of these protein and DNA conjugates as immune adjuvants and as vaccines for treatment of various chronic diseases such as HIV infection is also provided.

Adjuvant combinations comprising at least one microbial TLR agonist such as a whole virus, bacterium or yeast or portion thereof such a membrane, spheroplast, cytoplast, or ghost, a CD40 or 4-1BB agonist and optionally an antigen wherein all 3 moieties may be separate or comprise the same recombinant microorganism or virus are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers and HIV infection is also provided.

The invention relates to a saponin with immune adjuvant function and a preparation method thereof, a vaccine preparation containing the saponin as an adjuvant, and applications of the saponin and the vaccine preparation in the prevention and treatment of infectious diseases and cancers of human and animals. The saponin is platycodin D, platycodin D2, or a total-saponin containing the two saponin compounds. The platycodin D and platycodin D2 are both extracted and separated from balloonflower, a Chinese medicine. The saponin can induce an organism to generate Th1-type and Th2-type immune responses, show the capability of inducing the organism to generate stronger cell immune response and humoral immune response to a vaccine than the alhydrogel adjuvant known in the prior art, and can be taken as the immune adjuvant for a plurality of vaccines and achieve an ideal immunity effect. The vaccine which takes the saponin as the adjuvant has simple preparation technology and simple and convenient method, and the quality is easy to control and the saponin can be reserved by freezing.

The invention relates to compositions comprising a CD4 lymphocyte depleting agent; and methods of using the compositions to treat, prevent, reduce the severity of and / or slow the progression of a condition in a subject. The invention also relates to use of combinations of a CD4 lymphocyte depleting agent and at least one additional agent to treat, prevent, reduce the severity of and / or slow the progression of a condition in a subject. The additional agent may be an immune check point inhibitor, an adoptive immune therapeutic, an immune adjuvant, or an immune modulating agent, or their combinations.

The present invention discloses a CpG-ODN having a specific immuno-stimulatory effect on pigs and an application thereof. A nucleotide sequence of the CpG-ODN is shown in SEQ ID NO:1. The CpG-ODN canimprove induction of innate immunity and specific humoral and cell-mediated immune responses of the pigs, and can be transferred into a plasmid vector pFAR4 to construct a recombinant plasmid pFAR4-CpG to prepare a preparation containing the recombinant plasmid pFAR4-CpG. The preparation can effectively activate natural immune functions of the pigs, also successfully replaces or partially replaces antibiotics as an immune activator, can also effectively activate acquired immune functions of the pigs, especially cellular immunity, can be used as an immune adjuvant to improve a protective effect of vaccines, also has little toxic and side effects on body, has great potential, can be widely used in live pig breeding industry, and is conducive to reducing breeding cost, reducing incidence ofthe pigs, and improving survival rate and breeding efficiency.

The invention is directed to novel compounds of formulae (I), (II) and (III): wherein X is O or NH; R<3> is OH or a monosaccharide and R<4> is hydrogen, or R<3> is hydrogen and R<4> is OH or a monosaccharide; R<5> is hydrogen or a monosaccharide; and pharmaceutically acceptable salts or esters thereof. The invention is also directed to the use of the compounds both directly and as immune adjuvants for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the intermediates which can be used to make these novel compounds.

The invention discloses a swine trichinella spiralis vaccine as well as a preparation method and an application thereof. Firstly, a mature region of a gene TsCPB2 is amplified and cloned into an expression vector of a His tag, and then after transformation of escherichia coli and IPTG induced expression, TsCPB2 recombinant protein is purified by Ni-affinity chromatography, and a trichinella spiralis excretion-secretion recombinant antigen is obtained; TsCPB2 recombinant protein and an immune adjuvant are subjected to mixed emulsification, and the TsCPB2 recombinant antigen vaccine is obtained.With adoption of the vaccine for immunizing a mouse or swine, the host can be induced to produce an immune reaction, a good immunoprotective effect on trichinella spiralis infection is realized, andgreater application prospect is achieved.

The invention relates to the field of biomedicine and particularly to a hydrophobically modified antimicrobial peptide and a use thereof. The technical problem to be solved by the invention is to provide a hydrophobically modified antimicrobial peptide, the hydrophobic modification is to couple a hydrophobic fragment at the nitrogen terminal of the antimicrobial peptide. The invention further provides a micelle prepared from the hydrophobically modified antimicrobial peptide, and use of the hydrophobically modified antimicrobial peptide and the micelle in preparing antimicrobial drugs, nucleic acid transporter, immune adjuvant and the like. Due to small molecular weight, the antimicrobial peptide of the invention can be conveniently synthesized by Fmoc solid phase polypeptide, and coupled to a hydrophobic fragment by the chemical synthesis method in a simple and feasible way.

The invention relates to panax japonicus saponin used as a vaccine adjuvant as well as a preparation method and application thereof. The method comprises the following steps: extraction of the panax japonicus, extraction separation, resin adsorption and the like. The panax japonicus saponin is further separated and purified, the weaknesses of the traditional method that only the total saponins component is used and the main components of the samponin is not studied can be overcome, so that the problem that the drug ingredients are not known by people can be solved; an active part of the panax japonicus saponin has an obvious immunity adjuvant effect, and a way for developing the vaccine adjuvant is provided.

The invention provides a spirulina polysaccharide immune adjuvant and an influenza vaccine containing the same, wherein the spirulina polysaccharide immune adjuvant is prepared from the components in mass ratio as follows: 0.001-100% of spirulina polysaccharide and 0-99.999% of carrier, which is capable of preferably improving immunogenicity of the vaccine and greatly reducing dosage of antigen vaccine; the dosage of the antigen vaccine taking the spirulina polysaccharide as adjuvant is only a half of the dosage of the antigen vaccine taking the aluminum hydroxide as adjuvant or less, which can achieve ideal immune protection effect as well with high safety and small side effect; the influenza vaccine taking the spirulina polysaccharide as adjuvant is convenient for preparation and the quality thereof is easy to control.

The invention relates to an animal lyophilized inactivated vaccine and a preparation process thereof. The animal lyophilized inactivated vaccine comprises a separately-packaged immune adjuvant or diluent and a separately-packaged inactivated vaccine produced through vacuum freeze-drying, wherein vaccine antigen is inactivated and then is subjected to a vacuum freeze-drying process to obtain the inactivated vaccine, and the immune adjuvant or diluent has a good emulsifying performance. Compared with the animal lyophilized inactivated vaccine and the preparation process in the prior art, the animal lyophilized inactivated vaccine and the preparation process of the present invention have the following characteristics that: the vaccine can be subjected to freeze-drying to obtain the powdery or massive vaccine according to the immunizing dose of the single variety vaccine, the corresponding immune adjuvant is adopted to carry out preparation and use on site during use, and the fixed formulation is formed in a short time; farmers can selectively combine vaccines according to the requirements so as to well solve the problem of difficultly-achieved combined vaccine antigen content and further solve the defects of multiple immunization and too high immunizing dose of the traditional inactivated vaccine; and the difficult problem of short storage time of the inactivated vaccine is solved.

The invention discloses a complex immunity adjuvant. The adjuvant is prepared from the following components in percentage by weight: 1.5 to 3.5 percent of horttuyia cordala thunb polysaccharide, 0.2 to 0.55 percent of alanine, 0.8 to 2.2 percent of ginkgo leaf flavonoid, 5 to 8 percent of polyethylene castor oil, 5 to 8 percent of Span 80, 2.5 to 5 percent of polyethylene glycol, 6 to 10 percent of squalene, 30 to 35 percent of soybean oil for injection and 35 to 50 percent of water for injection, and the sum of the percentage by weight of the various components is 100 percent. The complex immunity adjuvant is safe and effective, can effectively enhance the immunostimulation capacity of PRRSV vaccines, and is suitable for immunoprophylaxis of porcine reproductive and respiratory syndrome (PRRS).